Neurodegenerative Market Forecast to 2013 (TA222)
40 Product Profiles
25+ Companies
Thousands of Metrics
Download Complimentary Report Summary
Comprehensive Forecasts for Neurodegenerative Conditions
The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:
- Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012.
- The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.
Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients' quality of life could see hundreds of millions - or even billions - of dollars in sales.
In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimer's, Multiple Sclerosis and Parkinson's markets.
Detailed Product Profiles
CEI's veteran analysts examine 40 brands representing different classes and stages of development. The profiled products represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:
- Current status of drug
- Sales position within its class
- Presence or strength of competition
Market growth opportunities:
- Analysis combines new/current sales or clinical trial info with projections, predictions, insights
- Analysis supported by sales projection charts, covering up to the next 7 years
- Materiality charts, for 2007 and 2012
- Charts containing market exclusivity and patent information for approved drugs
Clinical trial data tables to quickly show clinical detail:
- Describes trial and why drug is in its current stage
- Progress of drug
Analyses weigh the challenges and opportunities of each indication, class, and individual brand. Which brands will reap dividends and why? Whose sales are expected to drop? Which experimental therapies represent the next great medical breakthrough? Who will be the markets' leaders in the next decade?
Call Adam Bianchi at 919-403-6583 to get your own copy of "Neurodegenerative Market Forecast to 2013" today.
